Jensen CJ, Westendorf J, Wang MY, Wadsworth DP. Noni juice protects the liver. Eur J Gastroenterol Hepatol 2006;18:575-7. View abstract.
Jiménez-Encarnación E, Ríos G, Muñoz-Mirabal A, Vilá LM. Euforia-induced acute hepatitis in a patient with scleroderma. BMJ Case Rep 2012;2012. View abstract.
Koch E, Biber A. Treatment of rats with the Pelargonium sidoides extract EPs 7630 has no effect on blood coagulation parameters or on the pharmacokinetics of warfarin. Phytomedicine 2007;14 Suppl 6:40-5. View abstract.
Lim SL, Goh YM, Noordin MM, Rahman HS, Othman HH, Abu Bakar NA, Mohamed S. Morinda citrifolia edible leaf extract enhanced immune response against lung cancer. Food Funct. 2016;7(2):741-51. View abstract.
López-Cepero Andrada JM, Lerma Castilla S, Fernández Olvera MD, Amaya Vidal A. [Hepatotoxicity caused by a noni (Morinda citrifolia) preparation]. [Article in Spanish] Rev Esp Enferm Dig 2007;99:179-81. View abstract.
Mahattanadul S, Ridtitid W, Nima S, et al. Effects of Morinda citrifolia aqueous fruit extract and its biomarker scopoletin on reflux esophagitis and gastric ulcer in rats. J Ethnopharmacol 2011;134:243-50. View abstract.
Marchiori D, Zanello PP. Efficacy of N-acetylcysteine, D-mannose and Morinda citrifolia to treat recurrent cystitis in breast cancer survivals. In Vivo. 2017 Sep-Oct;31(5):931-936. View abstract.
McClatchey W. From Polynesian healers to health food stores: changing perspectives of Morinda citrifolia (Rubiaceae). Integr Cancer Ther 2002;1:110-20. View abstract.
McKoy ML, Thomas EA, Simon OR. Preliminary investigation of the anti-inflammatory properties of an aqueous extract from Morinda citrifolia (noni). Proc West Pharmacol Soc 2002;45:76-8. View abstract.
Millonig G, Stadlmann S, Vogel W. Herbal hepatotoxicity: acute hepatitis caused by a Noni preparation (Morinda citrifolia). Eur J Gastroenterol Hepatol 2005;17:445-7. View abstract.
Mueller BA, Scott MK, Sowinski KM, Prag KA. Noni juice (Morinda citrifolia): hidden potential for hyperkalemia? Am J Kidney Dis 2000;35:310-2. View abstract.
Murata K, Abe Y, Shinohara K, Futamura-Masuda M, Uwaya A, Isami F, Matsuda H. Anti-allergic activity of the Morinda citrifolia extract and its constituents. Pharmacognosy Res. 2014;6(3):260-5. View abstract.
Nima S, Kasiwong S, Ridtitid W, et al. Gastrokinetic activity of Morinda citrifolia aqueous fruit extract and its possible mechanism of action in human and rat models. J Ethnopharmacol. 2012;142(2):354-61. View abstract.
Nowak D, Goslinski M, Wesolowska A, Berenda K, Poplawski C. Effects of acute consumption of noni and chokeberry juices vs. energy drinks on blood pressure, heart rate, and blood glucose in young adults. Evid Based Complement Alternat Med. 2019;2019:6076751. View abstract.
Palu AK. TAHITIAN NONI® Juice: Its Antioxidant Capacity Is Only A Part of the Repertoires of Its Scientifically Proven Health Benefits What the Antioxidant Methods Actually Measure. Tahitian Noni International Research Center American Fork, Utah 2004;
Pawlus AD, Su BN, Keller WJ, Kinghorn AD. An anthraquinone with potent quinone reductase-inducing activity and other constituents of the fruits of Morinda citrifolia (noni). J Nat Prod 2005;68:1720-2. View abstract.
Potterat O, Felten R, Dalsgaard PW, Hamburger M. Identification of TLC markers and quantification by HPLC-MS of various constituents in noni fruit powder and commercial noni-derived products. J Agric Food Chem 2007;55:7489-94. View abstract.
Prapaitrakool S, Itharat A. Morinda citrifolia Linn. for prevention of postoperative nausea and vomiting. J Med Assoc Thai 2010;(93 Suppl 7):S204-9. View abstract.
Raj RK. Screening of indigenous plants for anthelmintic action against human Ascaris lumbricoides:Part II. Ind J Physiol Pharmacol 1975;19;47-9. View abstract.
Ratnoglik SL, Aoki C, Sudarmono P, Komoto M, Deng L, Shoji I, Fuchino H, Kawahara N, Hotta H. Antiviral activity of extracts from Morinda citrifolia leaves and chlorophyll catabolites, pheophorbide a and pyropheophorbide a, against hepatitis C virus. Microbiol Immunol. 2014;58(3):188-94. View abstract.
Samoylenko V, Zhao J, Dunbar DC, et al. New constituents from noni (Morinda citrifolia) fruit juice. J Agric Food Chem 2006;54:6398-402. View abstract.
Sharma K, Pachauri SD, Khandelwal K, Ahmad H, Arya A, Biala P, Agrawal S, Pandey RR, Srivastava A, Srivastav A, Saxena JK, Dwivedi AK. Anticancer Effects of Extracts from the Fruit of Morinda Citrifolia (Noni) in Breast Cancer Cell Lines. Drug Res (Stuttg). 2016;66(3):141-7. View abstract.
Stadlbauer V, Fickert P, Lackner C, et al. Hepatotoxicity of NONI juice: report of two cases. World J Gastroenterol 2005;11:4758-60. View abstract.
Stadlbauer V, Weiss S, Payer F, Stauber RE. Herbal does not at all mean innocuous: the sixth case of hepatotoxicity associated with morinda citrifolia (noni). Am J Gastroenterol 2008;103:2406-7. View abstract.
Wang MY, Lutfiyya N Weidenbacher-Hoper V Peng L Lipsky MS Anderson G. Morinda citrifolia L. (noni) improves the Quality of Life in adults with Osteoarthritis. Functional Foods in Health and Disease. 2011;2:75-90.
Wang MY, West BJ, Jensen CJ, et al. Morinda citrifolia (Noni): a literature review and recent advances in Noni research. Acta Pharmacol Sin 2002;23:1127-41. View abstract.
Young DS. Effects of Drugs on Clinical Laboratory Tests 4th ed. Washington: AACC Press, 1995.
Younos C, Rolland A, Fleurentin J, et al. Analgesic and behavioural effects of Morinda citrifolia. Planta Med 1990;56:430-4. View abstract.
Yu EL, Sivagnanam M, Ellis L, Huang JS. Acute hepatotoxicity after ingestion of Morinda citrifolia (noni berry) juice in a 14-year-old boy. J Pediatr Gastroenterol Nutr 2011;52:222-4. View abstract.
Yu-Chan Kang, Ming-Hong Chen, Shung-Lon Lai. Potentially Unsafe Herb-drug Interactions Between a Commercial Product of Noni Juice and Phenytoin- A Case Report. Acta Neurol Taiwan. 2015 Jun;24(2):43-6. View abstract.
Yuce B, Gulberg V, Diebold J, Gerbes AL. Hepatitis induced by noni juice from morinda citrifolia: a rare cause of hepatotoxicity or the tip of the iceberg? Digestion 2006;73:167-70. View abstract.
Abdel-Zaher, A. O., Ahmed, I. T., and El Koussi, A. D. The potential antidiabetic activity of some alpha-2 adrenoceptor antagonists. Pharmacol Res 2001;44(5):397-409. View abstract.
Abebe, W. An overview of herbal supplement utilization with particular emphasis on possible interactions with dental drugs and oral manifestations. J Dent.Hyg. 2003;77(1):37-46. View abstract.
Adeniyi, A. A., Brindley, G. S., Pryor, J. P., and Ralph, D. J. Yohimbine in the treatment of orgasmic dysfunction. Asian J Androl 2007;9(3):403-407. View abstract.
Adler, L. E., Hoffer, L., Nagamoto, H. T., Waldo, M. C., Kisley, M. A., and Giffith, J. M. Yohimbine impairs P50 auditory sensory gating in normal subjects. Neuropsychopharmacology 1994;10(4):249-257. View abstract.
Albus, M., Zahn, T. P., and Breier, A. Anxiogenic properties of yohimbine. I. Behavioral, physiological and biochemical measures. Eur.Arch.Psychiatry Clin.Neurosci. 1992;241(6):337-344. View abstract.
Albus, M., Zahn, T. P., and Breier, A. Anxiogenic properties of yohimbine. II. Influence of experimental set and setting. Eur Arch Psychiatry Clin Neurosci. 1992;241(6):345-351. View abstract.
Anden, N. E., Pauksens, K., and Svensson, K. Selective blockade of brain alpha 2-autoreceptors by yohimbine: effects on motor activity and on turnover of noradrenaline and dopamine. J Neural Transm. 1982;55(2):111-120. View abstract.
Andrejak, M., Ward, M., and Schmitt, H. Cardiovascular effects of yohimbine in anaesthetized dogs. Eur.J Pharmacol 10-28-1983;94(3-4):219-228. View abstract.
Anonymous. Yohimbine: time for resurrection? Lancet 11-22-1986;2(8517):1194-1195. View abstract.
Bagheri, H., Berlan, M., Montastruc, J. L., and Montastruc, P. Yohimbine and lacrimal secretion. Br J Clin Pharmacol. 1990;30(1):151-152. View abstract.
Bagheri, H., Bompart, G., Girolami, J. P., Montastruc, J. L., and Montastruc, P. Is yohimbine-induced increase in salivary secretion a kinin-dependent mechanism? Fundam.Clin Pharmacol 1992;6(1):17-20. View abstract.
Bagheri, H., Chale, J. J., Guyen, L. N., Tran, M. A., Berlan, M., and Montastruc, J. L. Evidence for activation of both adrenergic and cholinergic nervous pathways by yohimbine, an alpha 2-adrenoceptor antagonist. Fundam.Clin Pharmacol 1995;9(3):248-254. View abstract.
Bagheri, H., Schmitt, L., Berlan, M., and Montastruc, J. L. A comparative study of the effects of yohimbine and anetholtrithione on salivary secretion in depressed patients treated with psychotropic drugs. Eur.J Clin Pharmacol. 1997;52(5):339-342. View abstract.
Bagheri, H., Schmitt, L., Berlan, M., and Montastruc, J. L. Effect of 3 weeks treatment with yohimbine on salivary secretion in healthy volunteers and in depressed patients treated with tricyclic antidepressants. Br J Clin Pharmacol 1992;34(6):555-558. View abstract.
Balon R. The effects of anitdepressants on human sexuality: Diagnosis and management update 1999. Primary Psychology 1999;6(11):40-54.
Balon, R. Fluoxetine-induced sexual dysfunction and yohimbine. J Clin Psychiatry 1993;54(4):161-162. View abstract.
Berlan, M., Galitzky, J., Riviere, D., Foureau, M., Tran, M. A., Flores, R., Louvet, J. P., Houin, G., and Lafontan, M. Plasma catecholamine levels and lipid mobilization induced by yohimbine in obese and non-obese women. Int.J Obes. 1991;15(5):305-315. View abstract.
Berlin, I., Crespo-Laumonnier, B., Cournot, A., Landault, C., Aubin, F., Legrand, J. C., and Puech, A. J. The alpha 2-adrenergic receptor antagonist yohimbine inhibits epinephrine-induced platelet aggregation in healthy subjects. Clin Pharmacol.Ther. 1991;49(4):362-369. View abstract.
Berlin, I., Crespo-Laumonnier, B., Turpin, G., and Puech, A. J. The alpha-2 adrenoceptor antagonist yohimbine does not facilitate weight loss but blocks adrenaline induced platelet aggregation in obese subjects. Therapie 1989;44(4):301. View abstract.
Berlin, I., Stalla-Bourdillon, A., Thuillier, Y., Turpin, G., and Puech, A. J. [Lack of efficacy of yohimbine in the treatment of obesity]. J Pharmacol 1986;17(3):343-347. View abstract.
Betz, J. M., White, K. D., and der Marderosian, A. H. Gas chromatographic determination of yohimbine in commercial yohimbe products. J AOAC Int 1995;78(5):1189-1194. View abstract.
Biaggioni, I., Robertson, R. M., and Robertson, D. Manipulation of norepinephrine metabolism with yohimbine in the treatment of autonomic failure. J Clin Pharmacol. 1994;34(5):418-423. View abstract.
Bierer, L. M., Aisen, P. S., Davidson, M., Ryan, T. M., Stern, R. G., Schmeidler, J., and Davis, K. L. A pilot study of oral physostigmine plus yohimbine in patients with Alzheimer disease. Alzheimer Dis.Assoc.Disord. 1993;7(2):98-104. View abstract.
Bloomer, R. J., Canale, R. E., Blankenship, M. M., Hammond, K. G., Fisher-Wellman, K. H., and Schilling, B. K. Effect of the dietary supplement Meltdown on catecholamine secretion, markers of lipolysis, and metabolic rate in men and women: a randomized, placebo controlled, cross-over study. Lipids Health Dis 2009;8:32. View abstract.
Bolme, P., Corrodi, H., Fuxe, K., Hokfelt, T., Lidbrink, P., and Goldstein, M. Possible involvement of central adrenaline neurons in vasomotor and respiratory control. Studies with clonidine and its interactions with piperoxane and yohimbine. Eur J Pharmacol 1974;28(1):89-94. View abstract.
Boon, N. A., Elliott, J. M., Grahame-Smith, D. G., John-Green, T., and Stump, K. A comparison of alpha 2-adrenoreceptor binding characteristics of intact human platelets identified by [3H]-yohimbine and [3H]- dihydroergocryptine. J Auton.Pharmacol 1983;3(2):89-95. View abstract.
Bourin, M., Malinge, M., and Guitton, B. Provocative agents in panic disorder. Therapie 1995;50(4):301-306. View abstract.
Bowes, M. P., Peters, R. H., Kernan, W. J., Jr., and Hopper, D. L. Effects of yohimbine and idazoxan on motor behaviors in male rats. Pharmacol.Biochem.Behav. 1992;41(4):707-713. View abstract.
Braddock, L. E., Cowen, P. J., Elliott, J. M., Fraser, S., and Stump, K. Changes in the binding to platelets of [3H]imipramine and [3H]yohimbine in normal subjects taking amitriptyline. Neuropharmacology 1984;23(2B):285-286. View abstract.
Braddock, L., Cowen, P. J., Elliott, J. M., Fraser, S., and Stump, K. Binding of yohimbine and imipramine to platelets in depressive illness. Psychol.Med 1986;16(4):765-773. View abstract.
Bremner, J. D., Innis, R. B., Ng, C. K., Staib, L. H., Salomon, R. M., Bronen, R. A., Duncan, J., Southwick, S. M., Krystal, J. H., Rich, D., Zubal, G., Dey, H., Soufer, R., and Charney, D. S. Positron emission tomography measurement of cerebral metabolic correlates of yohimbine administration in combat-related posttraumatic stress disorder. Arch.Gen.Psychiatry 1997;54(3):246-254. View abstract.
Brodde, O. E., Anlauf, M., Arroyo, J., Wagner, R., Weber, F., and Buck, K. D. Hypersensitivity of adrenergic receptors and blood-pressure response to oral yohimbine in orthostatic hypotension. N.Engl.J Med 4-28-1983;308(17):1033-1034. View abstract.
Cameron, O. G., Zubieta, J. K., Grunhaus, L., and Minoshima, S. Effects of yohimbine on cerebral blood flow, symptoms, and physiological functions in humans. Psychosom.Med 2000;62(4):549-559. View abstract.
Charney, D. S., Heninger, G. R., and Redmond, D. E., Jr. Yohimbine induced anxiety and increased noradrenergic function in humans: effects of diazepam and clonidine. Life Sci. 7-4-1983;33(1):19-29. View abstract.
Charney, D. S., Heninger, G. R., and Sternberg, D. E. Assessment of alpha 2 adrenergic autoreceptor function in humans: effects of oral yohimbine. Life Sci 6-7-1982;30(23):2033-2041. View abstract.
Charney, D. S., Price, L. H., and Heninger, G. R. Desipramine-yohimbine combination treatment of refractory depression. Implications for the beta-adrenergic receptor hypothesis of antidepressant action. Arch.Gen.Psychiatry 1986;43(12):1155-1161. View abstract.
Chatelut, E., Rispail, Y., Berlan, M., and Montastruc, J. L. Yohimbine increases human salivary secretion. Br.J Clin Pharmacol. 1989;28(3):366-368. View abstract.
Cimolai, N. and Cimolai, T. Yohimbine use for physical enhancement and its potential toxicity. J Diet.Suppl 2011;8(4):346-354. View abstract.
Dwoskin, L. P., Neal, B. S., and Sparber, S. B. Evidence for antiserotonergic properties of yohimbine. Pharmacol Biochem.Behav. 1988;31(2):321-326. View abstract.
Ernst, E., Posadzki, P., and Lee, M. S. Complementary and alternative medicine (CAM) for sexual dysfunction and erectile dysfunction in older men and women: an overview of systematic reviews. Maturitas 2011;70(1):37-41. View abstract.
Fleurence, R., Williamson, R., Jing, Y., Kim, E., Tran, Q. V., Pikalov, A. S., and Thase, M. E. A systematic review of augmentation strategies for patients with major depressive disorder. Psychopharmacol.Bull. 2009;42(3):57-90. View abstract.
Friesen, K., Palatnick, W., and Tenenbein, M. Benign course after massive ingestion of yohimbine. J Emerg.Med 1993;11(3):287-288. View abstract.
Galitzky, J., Taouis, M., Berlan, M., Riviere, D., Garrigues, M., and Lafontan, M. Alpha 2-antagonist compounds and lipid mobilization: evidence for a lipid mobilizing effect of oral yohimbine in healthy male volunteers. Eur.J Clin Invest 1988;18(6):587-594. View abstract.
Giampreti, A., Lonati, D., Locatelli, C., Rocchi, L., and Campailla, M. T. Acute neurotoxicity after yohimbine ingestion by a body builder. Clin Toxicol.(Phila) 2009;47(8):827-829. View abstract.
Goldberg, M. R. and Robertson, D. Yohimbine: a pharmacological probe for study of the alpha 2- adrenoreceptor. Pharmacol Rev. 1983;35(3):143-180. View abstract.
Grossman, E., Rea, R. F., Hoffman, A., and Goldstein, D. S. Yohimbine increases sympathetic nerve activity and norepinephrine spillover in normal volunteers. Am J Physiol 1991;260(1 Pt 2):R142-R147. View abstract.
Gurguis, G. N., Vitton, B. J., and Uhde, T. W. Behavioral, sympathetic and adrenocortical responses to yohimbine in panic disorder patients and normal controls. Psychiatry Res. 6-16-1997;71(1):27-39. View abstract.
Guthrie, S. K., Hariharan, M., and Grunhaus, L. J. Yohimbine bioavailability in humans. Eur.J Clin Pharmacol 1990;39(4):409-411. View abstract.
Gyllenhaal, C., Merritt, S. L., Peterson, S. D., Block, K. I., and Gochenour, T. Efficacy and safety of herbal stimulants and sedatives in sleep disorders. Sleep Med Rev. 2000;4(3):229-251. View abstract.
Ho, A. K., Hoffman, D. B., Gershon, S., and Loh, H. H. Distribution and metabolism of tritiated yohimbine in mice. Arch.Int.Pharmacodyn.Ther 1971;194(2):304-315. View abstract.
Ho, C. C. and Tan, H. M. Rise of herbal and traditional medicine in erectile dysfunction management. Curr Urol.Rep. 2011;12(6):470-478. View abstract.
Holmes, A. and Quirk, G. J. Pharmacological facilitation of fear extinction and the search for adjunct treatments for anxiety disorders--the case of yohimbine. Trends Pharmacol Sci 2010;31(1):2-7. View abstract.
Jordan, J., Shannon, J. R., Biaggioni, I., Norman, R., Black, B. K., and Robertson, D. Contrasting actions of pressor agents in severe autonomic failure. Am J Med. 1998;105(2):116-124. View abstract.
Kennedy, S. H., Gnam, W., Ralevski, E., and Brown, G. M. Melatonin responses to clonidine and yohimbine challenges. J Psychiatry Neurosci. 1995;20(4):297-304. View abstract.
Kenney, W. L., Zappe, D. H., Tankersley, C. G., and Derr, J. A. Effect of systemic yohimbine on the control of skin blood flow during local heating and dynamic exercise. Am J Physiol 1994;266(2 Pt 2):H371-H376. View abstract.
Knoll, L. D., Benson, R. C., Jr., Bilhartz, D. L., Minich, P. J., and Furlow, W. L. A randomized crossover study using yohimbine and isoxsuprine versus pentoxifylline in the management of vasculogenic impotence. J Urol. 1996;155(1):144-146. View abstract.
Landis, E. and Shore, E. Yohimbine-induced bronchospasm. Chest 1989;96(6):1424. View abstract.
Le Corre, P., Dollo, G., Chevanne, F., and Le Verge, R. Biopharmaceutics and metabolism of yohimbine in humans. Eur J Pharm Sci 1999;9(1):79-84. View abstract.
Lebret, T., Herve, J. M., Gorny, P., Worcel, M., and Botto, H. Efficacy and safety of a novel combination of L-arginine glutamate and yohimbine hydrochloride: a new oral therapy for erectile dysfunction. Eur Urol. 2002;41(6):608-613. View abstract.
Mann, K., Klingler, T., Noe, S., Roschke, J., Muller, S., and Benkert, O. Effects of yohimbine on sexual experiences and nocturnal penile tumescence and rigidity in erectile dysfunction. Arch.Sex Behav. 1996;25(1):1-16. View abstract.
Mazo R and Sonda LP. A prospective double blind trial of yohimbine for erectile impotence [abstract]. 79th Annual Meeting of the American Urological Association, Baltimore 1984;234/A.
Melman A. The effects of yohimbine upon sexual function: a double-blind study [abstract]. 79th Annual Meeting of the American Urological Association, Baltimore :302/A.
Meyerbroeker, K., Powers, M. B., van, Stegeren A., and Emmelkamp, P. M. Does yohimbine hydrochloride facilitate fear extinction in virtual reality treatment of fear of flying? A randomized placebo-controlled trial. Psychother.Psychosom. 2012;81(1):29-37. View abstract.
Miller, W. W., Jr. Afrodex in the treatment of male impotence: a double-blind cross-over study. Curr.Ther.Res.Clin Exp. 1968;10(7):354-359. View abstract.
Montague, D. K., Barada, J. H., Belker, A. M., Levine, L. A., Nadig, P. W., Roehrborn, C. G., Sharlip, I. D., and Bennett, A. H. Clinical guidelines panel on erectile dysfunction: summary report on the treatment of organic erectile dysfunction. The American Urological Association. J Urol. 1996;156(6):2007-2011. View abstract.
Montastruc, J. L., Puech, A. J., Clanet, M., Guiraud-Chaumeil, B., and Rascol, A. [Yohimbine in treatment of Parkinson's disease. Preliminary results (author's transl)]. Nouv.Presse Med 4-11-1981;10(16):1331-1332. View abstract.
Montastruc, P., Berlan, M., and Montastruc, J. L. Effects of yohimbine on submaxillary salivation in dogs. Br J Pharmacol 1989;98(1):101-104. View abstract.
Morales, A. Yohimbine in erectile dysfunction: the facts. Int.J.Impot.Res. 2000;12 Suppl 1:S70-S74. View abstract.
Morales, A., Condra, M., Owen, J. A., Surridge, D. H., Fenemore, J., and Harris, C. Is yohimbine effective in the treatment of organic impotence? Results of a controlled trial. J Urol. 1987;137(6):1168-1172. View abstract.
Morales, A., Surridge, D. H., and Marshall, P. G. Yohimbine for treatment of impotence in diabetes. N.Engl.J Med 11-12-1981;305(20):1221. View abstract.
Morales, A., Surridge, D. H., Marshall, P. G., and Fenemore, J. Nonhormonal pharmacological treatment of organic impotence. J Urol. 1982;128(1):45-47. View abstract.
Morgan, C. A., III, Grillon, C., Southwick, S. M., Nagy, L. M., Davis, M., Krystal, J. H., and Charney, D. S. Yohimbine facilitated acoustic startle in combat veterans with post- traumatic stress disorder. Psychopharmacology (Berl) 1995;117(4):466-471. View abstract.
Morgan, C. A., III, Southwick, S. M., Grillon, C., Davis, M., Krystal, J. H., and Charney, D. S. Yohimbine-facilitated acoustic startle reflex in humans. Psychopharmacology (Berl) 1993;110(3):342-346. View abstract.
Mosqueda-Garcia, R., Fernandez-Violante, R., Tank, J., Snell, M., Cunningham, G., and Furlan, R. Yohimbine in neurally mediated syncope. Pathophysiological implications. J Clin Invest 11-15-1998;102(10):1824-1830. View abstract.
Motulsky, H. J., Shattil, S. J., and Insel, P. A. Characterization of alpha 2-adrenergic receptors on human platelets using [ View abstract.
Murburg, M. M., Villacres, E. C., Ko, G. N., and Veith, R. C. Effects of yohimbine on human sympathetic nervous system function. J Clin Endocrinol.Metab 1991;73(4):861-865. View abstract.
Musso, N. R., Vergassola, C., Pende, A., and Lotti, G. Yohimbine effects on blood pressure and plasma catecholamines in human hypertension. Am J Hypertens. 1995;8(6):565-571. View abstract.
Mustonen, P., Savola, J., and Lassila, R. Atipamezole, an imidazoline-type alpha(2)-adrenoceptor inhibitor, binds to human platelets and inhibits their adrenaline-induced aggregation more effectively than yohimbine. Thromb.Res 8-1-2000;99(3):231-237. View abstract.
Myers, A. and Barrueto, F., Jr. Refractory priapism associated with ingestion of yohimbe extract. J Med Toxicol. 2009;5(4):223-225. View abstract.
Okamoto, L. E., Shibao, C., Gamboa, A., Choi, L., Diedrich, A., Raj, S. R., Black, B. K., Robertson, D., and Biaggioni, I. Synergistic effect of norepinephrine transporter blockade and alpha-2 antagonism on blood pressure in autonomic failure. Hypertension 2012;59(3):650-656. View abstract.
Ostojic, S. M. Yohimbine: the effects on body composition and exercise performance in soccer players. Res Sports Med 2006;14(4):289-299. View abstract.
Papeschi, R. and Theiss, P. The effect of yohimbine on the turnover of brain catecholamines and serotonin. Eur J Pharmacol 1975;33(1):1-12. View abstract.
Piletz, J. E., Segraves, K. B., Feng, Y. Z., Maguire, E., Dunger, B., and Halaris, A. Plasma MHPG response to yohimbine treatment in women with hypoactive sexual desire. J Sex Marital Ther. 1998;24(1):43-54. View abstract.
Powers, M. B., Smits, J. A., Otto, M. W., Sanders, C., and Emmelkamp, P. M. Facilitation of fear extinction in phobic participants with a novel cognitive enhancer: a randomized placebo controlled trial of yohimbine augmentation. J Anxiety.Disord. 2009;23(3):350-356. View abstract.
Rasmusson, A. M., Hauger, R. L., Morgan, C. A., Bremner, J. D., Charney, D. S., and Southwick, S. M. Low baseline and yohimbine-stimulated plasma neuropeptide Y (NPY) levels in combat-related PTSD. Biol.Psychiatry 3-15-2000;47(6):526-539. View abstract.
Reid, K., Surridge, D. H., Morales, A., Condra, M., Harris, C., Owen, J., and Fenemore, J. Double-blind trial of yohimbine in treatment of psychogenic impotence. Lancet 8-22-1987;2(8556):421-423. View abstract.
Riley AJ, Goodman R, Kellett JM, and et al. Double blind trial of yohimbine hydrochloride in the treatment of erection inadequacy. Sexual Marital Ther 1989;4(1):17-26.
Rowland, D. L., Kallan, K., and Slob, A. K. Yohimbine, erectile capacity, and sexual response in men. Arch Sex Behav 1997;26(1):49-62. View abstract.
Shibao, C., Okamoto, L. E., Gamboa, A., Yu, C., Diedrich, A., Raj, S. R., Robertson, D., and Biaggioni, I. Comparative efficacy of yohimbine against pyridostigmine for the treatment of orthostatic hypotension in autonomic failure. Hypertension 2010;56(5):847-851. View abstract.
Siddiqui, M. A., More-O'Ferrall, D., Hammod, R. S., Baime, R. V., and Staddon, A. P. Agranulocytosis associated with yohimbine use. Arch.Intern.Med 6-10-1996;156(11):1235-1237. View abstract.
Soeter, M. and Kindt, M. Stimulation of the noradrenergic system during memory formation impairs extinction learning but not the disruption of reconsolidation. Neuropsychopharmacology 2012;37(5):1204-1215. View abstract.
Sonda, L. P., Mazo, R., and Chancellor, M. B. The role of yohimbine for the treatment of erectile impotence. J Sex Marital Ther. 1990;16(1):15-21. View abstract.
Southwick, S. M., Krystal, J. H., Bremner, J. D., Morgan, C. A., III, Nicolaou, A. L., Nagy, L. M., Johnson, D. R., Heninger, G. R., and Charney, D. S. Noradrenergic and serotonergic function in posttraumatic stress disorder. Arch.Gen.Psychiatry 1997;54(8):749-758. View abstract.
Sturgill, M. G., Grasing, K. W., Rosen, R. C., Thomas, T. J., Kulkarni, G. D., Trout, J. R., Maines, M., and Seibold, J. R. Yohimbine elimination in normal volunteers is characterized by both one- and two-compartment behavior. J Cardiovasc.Pharmacol. 1997;29(6):697-703. View abstract.
Susset, J. G., Tessier, C. D., Wincze, J., Bansal, S., Malhotra, C., and Schwacha, M. G. Effect of yohimbine hydrochloride on erectile impotence: a double-blind study. J Urol. 1989;141(6):1360-1363. View abstract.
Swann, A. C. Mechanisms of impulsivity in bipolar disorder and related illness. Epidemiol.Psichiatr.Soc. 2010;19(2):120-130. View abstract.
Swann, A. C., Birnbaum, D., Jagar, A. A., Dougherty, D. M., and Moeller, F. G. Acute yohimbine increases laboratory-measured impulsivity in normal subjects. Biol.Psychiatry 5-15-2005;57(10):1209-1211. View abstract.
Vogt, H. J., Brandl, P., Kockott, G., Schmitz, J. R., Wiegand, M. H., Schadrack, J., and Gierend, M. Double-blind, placebo-controlled safety and efficacy trial with yohimbine hydrochloride in the treatment of nonorganic erectile dysfunction. Int J Impot.Res 1997;9(3):155-161. View abstract.
Ashton AK. Yohimbine in the treatment of male erectile dysfunction. Am J Psychiatr 1994;151:1397. View abstract.
Balon R. Fluoxetine-induced sexual dysfunction and yohimbine. J Clin Psychiatry 1993;54:161-2. View abstract.
Balon R. The effects of anitdepressants on human sexuality: diagnosis and management update 1999. Primary Psychiatry 1999;6:40-54.
Barnes ME, Cowan CR, Boag LE, et al. Effects of Acute Yohimbine Hydrochloride Supplementation on Repeated Supramaximal Sprint Performance. Int J Environ Res Public Health 2022;19(3):1316. View abstract.
Bharucha AE, Skaar T, Andrews CN, et al Relationship of cytochrome P450 pharmacogenetics to the effects of yohimbine on gastrointestinal transit and catecholamines in healthy subjects. Neurogastroenterol Motil. 2008;20(8):891-9. View abstract.
Bucci LR. Selected herbals and human exercise performance. Am J Clin Nutr 2000;72:624S-36S.. View abstract.
Burnham TH, ed. Drug Facts and Comparisons, Updated Monthly. Facts and Comparisons, St. Louis, MO.
Cappiello A, McDougle CJ, Malison RT, et al. Yohimbine augmentation of Fluvoxamine in refactory depression: a single blind study. Biol Psychiatry 1995;38:765-7. View abstract.
Carey MP, Johnson BT. Effectiveness of yohimbine in the treatment of erectile disorder: four meta-analytic integrations. Arch Sex Behav 1996;25:341-60. View abstract.
Chevallier A. The Encyclopedia of Medicinal Plants. London, UK: Dorling Kindersley, Ltd., 1996.
Cohen PA, Wang YH, Maller G, DeSouza R, Khan IA. Pharmaceutical quantities of yohimbine found in dietary supplements in the USA. Drug Test Anal. 2015 Sep 22. View abstract.
Deuter CE, Smit J, Kaczmarczyk M, Wingenfeld K, Otte C, Kuehl LK. Approach-avoidance tendencies in depression and childhood trauma: No effect of noradrenergic stimulation. Compr Psychoneuroendocrinol 2021;8:100077. View abstract.
EFSA Panel on Food Additives and Nutrient Sources Added to Food (ANS). Scientific Opinion on the evaluation of the safety in use of Yohimbe (Pausinystalia yohimbe (K. Schum.) Pierre ex Beille). EFSA J. 2013;11(7):3302.
Elbe A, Foerster KI, Blank A, et al. Evaluation of CYP2C19 activity using microdosed oral omeprazole in humans. Eur J Clin Pharmacol 2022;78(6):975-987. View abstract.
Ernst E, Pittler MH. Yohimbine for erectile dysfunction: a systematic review and meta-analysis of randomized clinical trials. J Urol 1998;159:433-6.. View abstract.
Foster S, Tyler VE. Tyler's Honest Herbal, 4th ed., Binghamton, NY: Haworth Herbal Press, 1999.
Haron MH, Dale O, Martin K, et al. Evaluation of the Herb-Drug Interaction Potential of Commonly Used Botanicals on the US Market with Regard to PXR- and AhR-Mediated Influences on CYP3A4 and CYP1A2. J Diet Suppl 2022. View abstract.
Harvey KV, Balon R. Clinical implications of antidepressant drug effects on sexual function. Ann Clin Psychiatry 1995;7:189-201. View abstract.
Herman AM, Critchley HD, Duka T. The impact of yohimbine-induced arousal on facets of behavioural impulsivity. Psychopharmacology (Berl). 2019;236(6):1783-1795. View abstract.
Zhu L, Han X, Zhu J, Du L, Liu L, Gong W. Severe acute intoxication with yohimbine: Four simultaneous poisoning cases. Forensic Sci Int. 2021;320:110705. View abstract.
Select a condition to view a list of vitamins
CONDITIONS OF USE AND IMPORTANT INFORMATION: This information is meant to supplement, not replace advice from your doctor or healthcare provider and is not meant to cover all possible uses, precautions, interactions or adverse effects. This information may not fit your specific health circumstances. Never delay or disregard seeking professional medical advice from your doctor or other qualified health care provider because of something you have read on WebMD. You should always speak with your doctor or health care professional before you start, stop, or change any prescribed part of your health care plan or treatment and to determine what course of therapy is right for you.
This copyrighted material is licensed from Therapeutic Research Center, LLC. Information from this source is evidence-based and objective, and without commercial influence. For professional medical information on natural medicines, see Natural Medicines Comprehensive Database Professional Version.
Licensed from Therapeutic Research Center, LLC
Copyright © 1995-2024 by Therapeutic Research Center, LLC. All Rights Reserved.